Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (00874.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 13.08

From 52W high−34.95%

Volume1.97M

Market capHKD 21.43B

P/E (TTM)7.2x

P/S (TTM)0.2x

Div yield6.55%

Key dataSep 18, 2026

Open

HKD 13.08

From 52W high

−34.95%

Volume

1.97M

Market cap

HKD 21.43B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

3.9x

P/E (TTM)

7.2x

RSI (14)

26.6

MomentumView details →

1D Return

+0.53%

YTD Return

−25.62%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

7.2x

EV/EBITDA

3.9x

EV/Sales

0.2x

P/S (TTM)

0.2x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

15.28%

Net Margin

3.31%

EBITDA Margin

4.75%

ROE (TTM)

6.56%

ROA (TTM)

2.92%

Asset Turnover

0.88x

GrowthView details →

Revenue YoY

+2.38%

EPS YoY

−8.72%

FCF YoY

+917.45%

Revenue CAGR 3Y

+3.13%

EPS CAGR 3Y

−9.14%

EBITDA YoY

−4.86%

MomentumView details →

1D Return

+0.53%

YTD Return

−25.62%

1Y Return

−28.14%

RSI (14)

26.6

vs 50D SMA

−10.87%

vs 200D SMA

−21.50%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

0.20x

Quick Ratio

0.20x

Div Yield

6.55%

Div Rate

HKD 0.86

Div Growth 1Y

−1.50%

EarningsView details →

EPS (Actual)

HKD 0.22

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

77.59B

Net Income (TTM)

2.57B

Op. CF (TTM)

3.43B

Next earningsOct 27, 2026 →

Latest newsMore news →

Baiyunshan announced at its 2026 interim results briefing that more than 10 innovative drug pipeline in-licensing projects have completed project initiation, with a pipeline library of over 100 projects and nearly 50 BD innovative drug projects under evaluation.6d ago

Singapore biotech company LionTCR will work with Guangzhou Pharmaceutical Holdings to develop and accelerate the clinical translation of TCR-T cell therapies.25d ago

Similar companies

Aprogen Biologics Inc.003060.KS 天士力600535.SH 哈药股份600664.SH 济川药业600566.SH 皓元医药688131.SH Viatris Inc.VTRS Find similar companies →

Latest newsMore news →

Baiyunshan announced at its 2026 interim results briefing that more than 10 innovative drug pipeline in-licensing projects have completed project initiation, with a pipeline library of over 100 projects and nearly 50 BD innovative drug projects under evaluation.6d ago Singapore biotech company LionTCR will work with Guangzhou Pharmaceutical Holdings to develop and accelerate the clinical translation of TCR-T cell therapies.25d ago Baiyunshan proposed a cash dividend of 0.30 yuan per share (pre-tax) for the first half of 2026.30d ago